Is Teleflex (TFX) overvalued or fairly valued?

MarketChacha shows Teleflex's valuation in context — a forward P/E of about 12.6, a price-to-book of about 2.0 — alongside its revenue and profit growth and whether reported profit converts into operating cash, so you can judge value for yourself. MarketChacha does not issue ratings, price targets, or buy/sell advice.

What is Teleflex's revenue?

Teleflex reported revenue of $2.0B for FY2025, with net profit of $-905.6M, per official filings.

What is the share price of Teleflex (TFX)?

Teleflex last traded at $138.36 (-1.1% on the day), as of 9/4/2026 — a delayed quote shown for education, not investment advice.

Teleflex

TFX · NYSE · Healthcare · United States

Snapshot

TickerTFX

ExchangeNYSE

SectorHealthcare

IndustryMedical Instruments & Supplies

CountryUnited States

Employees15,500

HeadquartersWayne, United States

Websitewww.teleflex.com

Filings tracked25

About Teleflex

Teleflex Incorporated designs, develops, manufactures, and supplies single-use medical devices for common diagnostic and therapeutic procedures in critical care and surgical applications in the United States, Europe, the Middle East, Africa, the Asia Pacific, and internationally. The company offers vascular and emergency medicine products comprising Arrow branded catheters, catheter navigation and tip positioning systems, and intraosseous bone access systems for the administration of intravenous therapies, measurement of blood pressure, and collection of blood samples; intraosseous access systems consisting of EZ-IO intraosseous vascular access systems, and Arrow FAST1 sternal intraosseous infusion systems; and hemostatic products, including external hemostats and trauma products under the QuikClot brand. It also provides interventional products, including various coronary catheters, structural heart support devices, and peripheral intervention products platforms; GuideLiner, Turnpike, and TrapLiner catheters; MANTA vascular closure devices and Arrow OnControl powered bone biopsy systems; and coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters. In addition, the company offers surgical products, including metal and polymer ligating clips using manual and automatic applier system, fascial closure surgical systems used in laparoscopic surgical procedures, percutaneous surgical systems, powered bariatric staplers, and other surgical instruments under the Weck, MiniLap, Pleur-Evac, Deknatel, KMedic, Pilling, and Titan SGS brands. It serves hospitals, healthcare providers, and medical device manufacturers. The company also sells its products online. Teleflex Incorporated was incorporated in 1943 and is headquartered in Wayne, Pennsylvania.

Who owns it

Insiders0.6%
Institutions99.4%
Public & other0.0%

505 institutional holders

Ownership breakdown from public market data.

Top holders

Blackrock Inc.12.82%
Jupiter Topco LLC10.25%
T. Rowe Price Investment Management, Inc.7.54%
Vanguard Portfolio Management LLC5.70%
Vanguard Capital Management LLC4.71%
Sessa Capital IM, L.P.3.60%
State Street Corporation3.50%
Millennium Management Llc3.40%

Largest institutional holders — last updated 6/30/2026.

Forensic scorecard

Margin has compressed by about 66.3 points over the period — profitability is trending down.

Net margin trend20.8% → -45.4%

Margin has compressed by about 66.3 points over the period — profitability is trending down.

Return on equity-29.0%

Latest ROE of -29.0% is on the low side — the business earns a modest return on shareholder capital.

Computed by MarketChacha from reported figures (SEC XBRL). Education, not a rating or recommendation.

What's expected next

Next quarter

Rev $584.3M · EPS 2.12

Est. earnings growth +9.8%

Next fiscal year

Rev $2.4B · EPS 10.95

Est. earnings growth +54.8%

Analyst consensus estimates — not the company's own guidance.

New to these terms?

P/E ROE ROCE Margins Market cap

Browse the Learn hub →

Financials at a glance

Source: SEC XBRL

Annual

Quarterly · last 8

Revenue (FY2025)

$2.0B

Net margin

-45.4%

ROE

-29.0%

Revenue CAGR (2y)

+7.9%

EPS (FY2025)

-20.25

Net profit (FY2025)

$-905.6M

Ask MarketChacha about TFX

Get a cited, plain-English answer — the “why”, not just data. Finance research only, never buy/sell advice.

Financials

Yearly

Period	Revenue	Net profit	EPS	Net margin	ROE
FY2025	$2.0B	$-905.6M	-20.25	-45.4%	-29.0%
FY2024	$1.7B	$69.7M	1.48	4.1%	1.6%
FY2023	$1.7B	$356.3M	7.53	20.8%	8.0%

Quarterly

Period	Revenue	Net profit	EPS	Net margin
2026Q2	$570.3M	$99.7M	2.28	17.5%
2026Q1	$548.3M	$-8.2M	-0.18	-1.5%
2025Q4	$569.0M	$-714.3M	-16.15	-125.5%
2025Q3	$566.9M	$-408.9M	-9.24	-72.1%
2025Q2	$442.5M	$122.6M	2.77	27.7%
2025Q1	$414.3M	$95.0M	2.07	22.9%
2024Q4	$442.0M	$-136.7M	-2.93	-30.9%
2024Q3	$426.2M	$111.0M	2.36	26.0%
2024Q2	$418.5M	$80.0M	1.69	19.1%
2024Q1	$412.8M	$15.3M	0.32	3.7%
2023Q4	$746.4M	$137.1M	2.90	18.4%
2023Q3	$743.3M	$111.3M	2.35	15.0%
2023Q2	$710.9M	$76.7M	1.62	10.8%

Figures as reported, in reporting currency. Source: SEC XBRL.

Filings & announcements

2026

8-K — Other events
SEC8/7/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC8/6/2026material
10-Q filing
SEC8/6/2026
8-K/A — Exhibits
SEC8/5/2026
8-K — Completion of acquisition/disposition, Reg FD disclosure, Exhibits
SEC8/3/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC6/15/2026material
8-K — Executive/director change
SEC6/9/2026material
8-K — Other events, Exhibits
SEC6/2/2026material
8-K — Reg FD disclosure, Other events, Exhibits
SEC6/1/2026material
8-K — Material agreement, Material financial obligation, Exhibits
SEC5/27/2026material
8-K — Shareholder vote results
SEC5/20/2026material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC5/7/2026material
10-Q filing
SEC5/7/2026
8-K — Executive/director change, Exhibits
SEC4/30/2026material
8-K — Reg FD disclosure, Exhibits
SEC3/27/2026material
8-K — Other events
SEC3/17/2026material
10-K filing
SEC2/27/2026
8-K — Results of operations, Costs from exit/disposal, Reg FD disclosure, Exhibits
SEC2/26/2026material
8-K — Executive/director change
SEC1/23/2026material
8-K — Results of operations, Executive/director change, Exhibits
SEC1/8/2026material

2025

8-K — Material agreement, Reg FD disclosure, Other events, Exhibits
SEC12/9/2025material
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC11/6/2025material
10-Q filing
SEC11/6/2025
8-K — Results of operations, Reg FD disclosure, Exhibits
SEC7/31/2025material
10-Q filing
SEC7/31/2025

In the news

Education and discussion only — not investment advice. Financials from official filings (SEC/BSE) and reported company statements; market figures (delayed market data) are delayed and shown for reference only. Verify with the linked sources before acting.